CD4 and neoplasm: Using a B16F10 murine model of melanoma, Binneswies et al. studied myeloid cells in tumor-draining lymph nodes and found that type II dendritic cells present tumor-derived antigens to conventional CD4+ T-cells and their abundance correlated with conventional CD4+ T-cells and patient survival.